Lucid Diligence Brief - BioPharma

Ascidian and Lilly $1.9B Deal for Kidney RNA Editing | Lucid Diligence Brief

Ascidian and Lilly $1.9B collaboration tests whether RNA exon editing can move…


Cell_Gene_Therapy

Cell and Gene Therapy Weekly News - May 22nd 2025

This Week in Gene & Cell Therapy: Personalized CRISPR, FDA Clearances, and…


Privacy Preference Center